Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CEO Sells $233,679.68 in Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Matthew Klein sold 3,016 shares of PTC Therapeutics stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $77.48, for a total value of $233,679.68. Following the completion of the sale, the chief executive officer owned 396,967 shares of the company’s stock, valued at approximately $30,757,003.16. The trade was a 0.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

PTC Therapeutics Trading Up 0.9%

PTC Therapeutics stock opened at $77.53 on Friday. The company has a market cap of $6.22 billion, a PE ratio of 9.06 and a beta of 0.49. PTC Therapeutics, Inc. has a 1 year low of $35.95 and a 1 year high of $87.50. The company’s 50-day moving average is $76.61 and its two-hundred day moving average is $62.81.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.19) by $1.39. PTC Therapeutics had a net margin of 42.25% and a negative return on equity of 194.11%. The business had revenue of $211.01 million during the quarter, compared to the consensus estimate of $177.42 million. During the same period in the previous year, the firm posted ($1.39) earnings per share. PTC Therapeutics’s revenue for the quarter was up 7.2% compared to the same quarter last year. Research analysts forecast that PTC Therapeutics, Inc. will post -4.52 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on PTCT shares. Cowen reaffirmed a “hold” rating on shares of PTC Therapeutics in a research note on Wednesday, November 5th. Wall Street Zen upgraded PTC Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of PTC Therapeutics in a research note on Monday, December 29th. Royal Bank Of Canada lowered shares of PTC Therapeutics from an “outperform” rating to a “sector perform” rating and lifted their price objective for the stock from $82.00 to $91.00 in a research note on Monday, December 1st. Finally, Jefferies Financial Group upped their target price on shares of PTC Therapeutics from $63.00 to $77.00 and gave the company a “buy” rating in a research note on Tuesday, October 28th. Nine research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $77.27.

Key PTC Therapeutics News

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Recent quarterly results showed an upside surprise (EPS and revenue beat), supporting valuation and reducing near-term execution risk. MarketBeat PTCT Summary
• Positive Sentiment: At least one independent researcher upgraded PTC from Hold to Buy (Wall Street Zen), and several firms have raised price targets in November — a bullish offset to otherwise muted analyst sentiment. Wall Street Zen Upgrade
• Neutral Sentiment: Analysts as a group still carry a consensus “Hold” rating on PTCT, indicating limited immediate upside from broker consensus alone. Analyst Consensus
• Neutral Sentiment: The company reported a routine inducement grant of 300 RSUs for a new non-executive hire under Nasdaq rules — small dilution and not material to fundamentals. PR Newswire
• Negative Sentiment: A director executed a large sale totaling $916,200, a notable insider disposition that can weigh on sentiment. Director Sale
• Negative Sentiment: Broad insider selling reported in multiple SEC Form 4 filings (CEO, CFO, EVP, VP, CAO and others sold shares in early January). The scale and breadth of executive sales likely represent profit-taking or diversification and can create short-term downward pressure until offset by fresh operational news. Representative SEC filing: SEC Form 4
• Negative Sentiment: EVP Lee Scott Golden and other insiders sold modest-to-large blocks (multiple transactions disclosed), reinforcing the headline of concentrated insider exits. InsiderTrades Alert

Hedge Funds Weigh In On PTC Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Jefferies Financial Group Inc. acquired a new stake in PTC Therapeutics during the 3rd quarter worth approximately $97,252,000. SG Americas Securities LLC increased its position in shares of PTC Therapeutics by 587.5% during the fourth quarter. SG Americas Securities LLC now owns 894,461 shares of the biopharmaceutical company’s stock worth $67,943,000 after acquiring an additional 764,364 shares in the last quarter. Hood River Capital Management LLC raised its holdings in shares of PTC Therapeutics by 654.4% during the second quarter. Hood River Capital Management LLC now owns 636,502 shares of the biopharmaceutical company’s stock worth $31,087,000 after acquiring an additional 552,130 shares during the period. State Street Corp raised its holdings in shares of PTC Therapeutics by 22.1% during the second quarter. State Street Corp now owns 2,996,454 shares of the biopharmaceutical company’s stock worth $146,347,000 after acquiring an additional 541,558 shares during the period. Finally, Palo Alto Investors LP lifted its position in PTC Therapeutics by 112.2% in the 3rd quarter. Palo Alto Investors LP now owns 862,613 shares of the biopharmaceutical company’s stock valued at $52,939,000 after acquiring an additional 456,144 shares in the last quarter.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.